TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17086057

Group type: EXPERIMENTAL
Intervention: pegIFNalpha-2a (40KD) plus ribavirin
Number of subjects: 860

Group type: COMPARATOR
Intervention: pegIFNalpha-2a (40KD) plus placebo
Number of subjects: 860

Group type: COMPARATOR
Intervention: IFNalpha-2a plus ribavirin
Number of subjects: 860
Study: 12657845

Group type: EXPERIMENTAL
Intervention: BIS monitoring (Aspect Medical Systems, Natick, MA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No BIS monitoring
Number of subjects: 99
Study: 10826397

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Stress (exam)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Caffeine + Stress
Number of subjects: 31
Study: 8638454

Group type: EXPERIMENTAL
Intervention: 75g oral glucose tolerance test (OGTT) performed first
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50g oral glucose tolerance test (OGTT)
Number of subjects: 0
Study: 1993488

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole 3 days a week
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole once daily
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 6149125

Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30901344

Group type: EXPERIMENTAL
Intervention: Oral rifampicin and trimethoprim/sulfamethoxazole for 21 days (arm A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Observational group (arm B)
Number of subjects: 61
Study: 29972753

Group type: EXPERIMENTAL
Intervention: Patisiran (0.3 mg/kg IV every 3 weeks)
Number of subjects: 225
Study: 25689953

Group type: EXPERIMENTAL
Intervention: Limited Access Dressing (LAD)
Number of subjects: 55
Study: 24268548

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Good patient-physician relationship
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Living with a heroin user
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Lack of good relationship with physician
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cocaine use during treatment
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Hazardous alcohol consumption at enrolment
Number of subjects: 158
Study: 22978476

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham EA)
Number of subjects: 316

Group type: COMPARATOR
Intervention: No Electroacupuncture (no-EA)
Number of subjects: 316
Study: 19806599

Group type: EXPERIMENTAL
Intervention: Adapted virtual reality cognitive training program (10 sessions, 2 VR activities using IREX)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual programs in the setting (control group)
Number of subjects: 27
Study: 17609909

Group type: EXPERIMENTAL
Intervention: Baoshen Mixture (BSM) given orally thrice a day, 150 mL every time for 15 successive days
Number of subjects: 400

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control group)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Both groups received one cycle of chemotherapy program of 28‐30 days with conventional hydratization, alkalization and chloridization
Number of subjects: 400
Study: 17378193

Group type: EXPERIMENTAL
Intervention: Mild moxibustion combined with cupping therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 0
Study: 15622367

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 1 g with normal saline before and after angiography
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (nothing)
Number of subjects: 94

Group type: COMPARATOR
Intervention: NAC and Placebo in raised SC group
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: NAC (i.v. at 1 g)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Normal SC group (hydration)
Number of subjects: 94
Study: 10874267

Group type: EXPERIMENTAL
Intervention: Intravenous RPR 109891
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Oral RPR 109891
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Intravenous plus oral RPR 109891
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 9179324

Group type: EXPERIMENTAL
Intervention: Literature-based reading project
Number of subjects: 0
Study: 8252506

Group type: EXPERIMENTAL
Intervention: leuprolide and flutamide
Number of subjects: 603

Group type: COMPARATOR
Intervention: leuprolide and placebo
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: flutamide after progression
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: leuprolide and flutamide at disease progression
Number of subjects: 603
Study: 3899677

Group type: EXPERIMENTAL
Intervention: Vinpocetine 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30325677

Group type: EXPERIMENTAL
Intervention: Guided graded Exercise Self-help (GES)
Number of subjects: 19
Study: 29172403

Group type: EXPERIMENTAL
Intervention: Circulating renalase levels
Number of subjects: 383

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 383
Study: 27859314

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (study group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard definition of margins (control group)
Number of subjects: 100
Study: 26941545

Group type: EXPERIMENTAL
Intervention: E‐LRP+LIHR
Number of subjects: 60

Group type: COMPARATOR
Intervention: E‐LRP
Number of subjects: 60
Study: 24747090

Group type: EXPERIMENTAL
Intervention: Increased body mass index (BMI)
Number of subjects: 3258
Study: 20661162

Group type: EXPERIMENTAL
Intervention: Ballistic strength training (BST) for 8 weeks, 2 times a week
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 19155764

Group type: EXPERIMENTAL
Intervention: Intracranial stenting (Wingspan and Neurolink Stent Systems)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical therapy (including cilostazol)
Number of subjects: 0
Study: 17704423

Group type: EXPERIMENTAL
Intervention: LV5FU2 (semimonthly regimen)
Number of subjects: 905

Group type: COMPARATOR
Intervention: mFU/LV (monthly regimen)
Number of subjects: 905
Study: 15185766

Group type: EXPERIMENTAL
Intervention: ACNU
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACNU plus procarbazine
Number of subjects: 0
Study: 11230476

Group type: EXPERIMENTAL
Intervention: Three courses of mitomycin 8 mg/m(2), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) every 21 days.
Number of subjects: 308

Group type: COMPARATOR
Intervention: Six courses of mitomycin 8 mg/m(2), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) every 21 days.
Number of subjects: 308
Study: 9746385

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg (n = 218)
Number of subjects: 437

Group type: COMPARATOR
Intervention: E2/NETA (17beta‐oestradiol 2 mg plus norethisterone acetate 1 mg) (n = 219)
Number of subjects: 437
Study: 2894492

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 500 and 2000 micrograms thrice in 1 day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 750 micrograms thrice daily for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30788847

Group type: EXPERIMENTAL
Intervention: Ticagrelor (60 mg twice daily, reduced from 90 mg twice daily)
Number of subjects: 19220

Group type: COMPARATOR
Intervention: Placebo (on top of low dose aspirin)
Number of subjects: 19220

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 19220
Study: 28575235

Group type: EXPERIMENTAL
Intervention: Active remote monitoring (RM)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1650
Study: 25639879

Group type: EXPERIMENTAL
Intervention: Submicron indomethacin 40 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Submicron indomethacin 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indomethacin 50 mg
Number of subjects: 40
Study: 23815915

Group type: EXPERIMENTAL
Intervention: VD regimen (bortezomib combined with dexamethasone)
Number of subjects: 59

Group type: COMPARATOR
Intervention: VAD regimen (vincristine, doxorubicin, and dexamethasone)
Number of subjects: 59
Study: 22384544

Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) at a daily dose of 1.2 g, twice daily (large dose group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) at a daily dose of 0.6 g, twice daily (normal dose group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) (both doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (routine therapy only)
Number of subjects: 80
Study: 19524823

Group type: EXPERIMENTAL
Intervention: Bonded Herbst followed by fixed appliances (BH + FA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Headgear followed by fixed appliances and Class II elastics (HG + FA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Natural growth changes in Class II controls
Number of subjects: 56
Study: 16721690

Group type: EXPERIMENTAL
Intervention: Serrated adenomas (SA) with size <10 mm
Number of subjects: 71

Group type: COMPARATOR
Intervention: Serrated adenomas (SA) with size >=10 mm
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Protruded serrated adenomas
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Superficial serrated adenomas
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Histopathological features of serrated adenomas
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Dysplasia levels in serrated adenomas
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: IV and III L pit SAs
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hyperplastic polyps-like SAs
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Atypia in II pit SAs
Number of subjects: 71
Study: 15650469

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Electrical heat acupuncture (EH)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 12645048

Group type: EXPERIMENTAL
Intervention: Criminal anchoring in suspect statements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-temporal sequence of events in statements
Number of subjects: 0
Study: 10601068

Group type: EXPERIMENTAL
Intervention: Somatostatin plus isosorbide 5-mononitrate (250 microg/hour + 40 mg/12 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Somatostatin alone (placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Somatostatin plus isosorbide 5-mononitrate
Number of subjects: 60
Study: 9362350

Group type: EXPERIMENTAL
Intervention: TIPSS
Number of subjects: 58

Group type: COMPARATOR
Intervention: VBL
Number of subjects: 58
Study: 1313860

Group type: EXPERIMENTAL
Intervention: eight‐drugs‐in‐one‐day
Number of subjects: 35

Group type: COMPARATOR
Intervention: PCV
Number of subjects: 35
Study: 2427983

Group type: EXPERIMENTAL
Intervention: Combined radiochemotherapy (4 courses + 40 Gy EF)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Chemotherapy (4 courses + 20 Gy EF)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: TNI 40 Gy
Number of subjects: 235

Group type: COMPARATOR
Intervention: 6 courses chemotherapy + 20 Gy IF
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Consolidation therapy 20 Gy IF
Number of subjects: 235

Group type: COMPARATOR
Intervention: 2 courses chemotherapy
Number of subjects: 235
Study: 30055903

Group type: EXPERIMENTAL
Intervention: Apomorphine infusion (mean final dose 4·68 mg/h)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo saline infusion
Number of subjects: 106
Study: 27665230

Group type: COMPARATOR
Intervention: IONIS‐APO(a)Rx
Number of subjects: 122

Group type: COMPARATOR
Intervention: IONIS‐APO(a)‐LRx 10 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: IONIS‐APO(a)‐LRx 20 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: IONIS‐APO(a)‐LRx 40 mg
Number of subjects: 122
Study: 25047762

Group type: EXPERIMENTAL
Intervention: A combination of nuclear β-catenin and atypical scores
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Nuclear β-catenin
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Atypical scores
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Nuclear β-catenin immunoreactivity
Number of subjects: 136
Study: 22440085

Group type: EXPERIMENTAL
Intervention: Atonia Index (quantitative analysis of chin EMG during REM sleep)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal controls (no specific intervention mentioned)
Number of subjects: 27
Study: 19550338

Group type: EXPERIMENTAL
Intervention: Low-inspired oxygen concentration
Number of subjects: 142

Group type: COMPARATOR
Intervention: High-inspired oxygen concentration
Number of subjects: 142
Study: 18757085

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/day
Number of subjects: 5926

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5926
Study: 15750445

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 63
Study: 12872466

Group type: EXPERIMENTAL
Intervention: Fluoroscopy during colonoscopy (Group B)
Number of subjects: 264

Group type: COMPARATOR
Intervention: No fluoroscopy during colonoscopy (Group A)
Number of subjects: 264
Study: 10558453

Group type: EXPERIMENTAL
Intervention: Diuretics and beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine (in combination with other antihypertensive drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril and Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydropyridine
Number of subjects: 0
Study: 7867364

Group type: EXPERIMENTAL
Intervention: Evidence-based recommendations from clinical trials
Number of subjects: 0
Study: 1958599

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7181807

Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system‐scopolamine (1.0 mg over 3 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system‐scopolamine (second treatment regimen)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (four treatments)
Number of subjects: 6
Study: 31428820

Group type: EXPERIMENTAL
Intervention: CT-P6
Number of subjects: 549

Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 549
Study: 27193248

Group type: EXPERIMENTAL
Intervention: Explicit video-based warm-up
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Implicit video-based warm-up
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no video-based warm-up)
Number of subjects: 30
Study: 25337966

Group type: EXPERIMENTAL
Intervention: Adductor Canal (AC) technique with 8 mL of 2% lidocaine with epinephrine 1:400,000
Number of subjects: 102

Group type: COMPARATOR
Intervention: Peri-saphenous branch of the descending genicular artery (Peri-SBDGA) technique with 8 mL of 2% lidocaine with epinephrine 1:400,000
Number of subjects: 102
Study: 23810152

Group type: EXPERIMENTAL
Intervention: Pasteurized raw whole egg powder (1 teaspoon daily from 4 to 8 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Rice powder (1 teaspoon daily from 4 to 8 months)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Pasteurized raw whole egg powder
Number of subjects: 86
Study: 21675058

Group type: EXPERIMENTAL
Intervention: Daily Sedative Interruption (DSI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Continuous Sedation (CS)
Number of subjects: 22
Study: 19755166

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 49

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 49
Study: 16723518

Group type: EXPERIMENTAL
Intervention: Pursuit eye movement during visual flow stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retinal flow stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pursuit eye movement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotational flow relative to the head
Number of subjects: 0
Study: 15028375

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 100
Study: 11585144

Group type: EXPERIMENTAL
Intervention: 4‐META/MMA‐TBB resin cement, bonded through the root canal (group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 4‐META/MMA‐TBB resin cement, bonded extra-orally and replanted (group B)
Number of subjects: 22
Study: 9509698

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrinolytic therapy
Number of subjects: 0
Study: 8015504

Group type: EXPERIMENTAL
Intervention: dl-norgestrel alone (0.075 mg/day) continuously for two cycles
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination therapy (dl-norgestrel and estradiol-17 beta) for six cycles
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: dl-norgestrel alone (0.075 mg/day) for two cycles
Number of subjects: 26
Study: 2597712

Group type: EXPERIMENTAL
Intervention: Behavioral Stepped-Care treatment program (systolic feedback)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Behavioral Stepped-Care treatment program (relaxation)
Number of subjects: 15
Study: 53554

Group type: EXPERIMENTAL
Intervention: Cimetidine 0.8 g/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cimetidine 1.6 g/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6252915

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 6
Study: 30932564

Group type: EXPERIMENTAL
Intervention: Fault-tolerant gates implemented in the code space using the [4,2,2] code
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physically equivalent gates implemented on physical qubits
Number of subjects: 0
Study: 29345724

Group type: EXPERIMENTAL
Intervention: Cognitive training (12-week program, twice a week for 45 minutes)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (day care as usual)
Number of subjects: 147
Study: 27698953

Group type: EXPERIMENTAL
Intervention: DHA supplementation (1.14 g/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 8-week training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 8-week training with DHA supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 16
Study: 24121690

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 713

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 713

Group type: COMPARATOR
Intervention: Natural Cycle
Number of subjects: 713
Study: 22649264

Group type: EXPERIMENTAL
Intervention: Low-glycemic load meal
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-glycemic load meal
Number of subjects: 40
Study: 19212881

Group type: EXPERIMENTAL
Intervention: Asymptotic confidence interval approaches for the difference of proportions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method adding two successes and two failures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two examples illustrating the usage of the proposed methods
Number of subjects: 0
Study: 17140647

Group type: EXPERIMENTAL
Intervention: Fluticasone monotherapy
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: PACT combination
Number of subjects: 285

Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 285
Study: 14557438

Group type: EXPERIMENTAL
Intervention: Oral estradiol (1 mg every 12 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (200 micro g/d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 micro g/d)
Number of subjects: 9
Study: 11145491

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1510
Study: 8984849

Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Haloperidol 10 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Risperidone (various doses)
Number of subjects: 99
Study: 1311964

Group type: EXPERIMENTAL
Intervention: 60 mg oral dose of dl-fenfluramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2992724

Group type: EXPERIMENTAL
Intervention: Five-drug combination (vincristine, doxorubicin, cisplatin, etoposide, cyclophosphamide)
Number of subjects: 56
Study: 31831079

Group type: EXPERIMENTAL
Intervention: FKB327
Number of subjects: 730

Group type: COMPARATOR
Intervention: RP
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 730
Study: 28923138

Group type: EXPERIMENTAL
Intervention: Trained group (exposed to a provocative rotating virtual scene)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained group (control group)
Number of subjects: 0
Study: 25588320

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam microdose (0.001 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous midazolam regular dose (1 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral midazolam microdose (0.003 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral midazolam regular dose (3 mg)
Number of subjects: 16
Study: 23551803

Group type: EXPERIMENTAL
Intervention: Calcitonin nasal spray 200 IU
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline (placebo) spray
Number of subjects: 46
Study: 22108481

Group type: EXPERIMENTAL
Intervention: Pycnogenol® supplementation for 8 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (equivalent students)
Number of subjects: 53
Study: 19738321

Group type: EXPERIMENTAL
Intervention: L-DOPA 100 mg daily for 5 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17218915

Group type: EXPERIMENTAL
Intervention: Vitrectomy with arteriovenous sheathotomy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vitrectomy without arteriovenous sheathotomy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (with and without sheathotomy)
Number of subjects: 36